LDL cholesterol apheresis treatment for diabetic nephropathy with severe urinary protein: a multicenter prospective study

LDL cholesterol apheresis treatment for diabetic nephropathy with severe urinary protein: a multicenter prospective study - LICENSE study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014875

Enrollment

Registered

2014-10-01

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

LDL apheresis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Clinically diagnosed diabetic nephropathy fulfills the following criteria within 3 months before enrollment; -urinary protein/urinary creatinine equal or more than 3g/gCr or 3g/day -serum creatinine less than 2mg/dL 2)Age matched or older than 20 years and younger than 75 years

Exclusion criteria

Exclusion criteria: -Dialysis patients -Post renal transplantation or nephrectomy -Past history undergoing LDL apheresis -Undergoing surgical procedure including revascularization within 6 month before enrollment -proliferating diabetic retinopathy or severe diabetic neuropathy -Peripheral artery disease (Rutherford class 5 or more) or post amputation

Design outcomes

Primary

Measure	Time frame
Ratio of achievement of more than 30% decrease in urinary protein/urinary creatinine	—

Countries

Japan

Contacts

Public ContactTakashi Wada

Kanazawa University Department of Nephrology and Laboratory Medicine

lab-med@med.kanazawa-u.ac.jp076-265-2000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026